Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06168019

Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Government. Medical College Hospital, Nagpur, India

Loading trial locations.

About this study

All pregnant women enrolled in the study will receive standard of care throughout their pregnancy, labor and delivery and post-partum to discharge. Wherever possible, study visits will coincide with regular antenatal (ANC) care and blood draws will be added to standard blood draws during ANC, labor and delivery and postpartum care. Women will be counselled about procedure to reduce the risk of acquiring ORV during pregnancy. Since this study is observational, we do not anticipate any specific safety concerns with study interviews and procedures, but the investigators will monitor potential adverse events to determine if they are likely or possibly study related.

PRIMARY OBJECTIVE: Determine the prevalence, incidence, and maximal severity of symptomatic or asymptomatic COVID-19 in pregnant women to day 42 postpartum/after miscarriage on maternal outcomes. Secondary analysis will evaluate whether influenza/Other Respiratory Viruses (ORV) infection or COVID-19 vaccination modifies or mediates this risk.

SECONDARY OBJECTIVE: Determine the effect of maternal COVID-19 infection on the fetus and/or neonate during pregnancy through day 7 of life. Secondary analysis will focus on whether influenza/ORV or vaccination modifies, and pre-term birth mediates this risk.

EXPLORATORY OBJECTIVE: Characterize patterns and trajectories of host response/ inflammatory biomarkers as potential mediators of COVID-19 ± Influenza and ORV infection on progression to severe illness in pregnant women/mothers admitted to Government Medical College hospital with COVID-19. Modifiers include COVID-19 , Influenza and other ORV vaccinations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women aged 18 to 50 years registering for antenatal care (ANC) at Government Medical College Hospital (GMC) Nagpur, India

  • Estimated Gestational Age at registration <14 weeks based on ultrasound report at the baseline study visit;
  • Intends to receive pregnancy, labor and delivery and neonatal care at GMC;
  • Plans to live within the city limits of Nagpur throughout their pregnancy and labor and delivery to facilitate access to GMC for evaluation of ILI and COVID-19 symptoms;
  • Willing to be contacted two times per week by call or text for ILI/ COVID-19 symptom screening and return to GMC for evaluation and an NP swab/evaluation if symptoms are reported;
  • Willing to take temperature with the provided digital thermometer, and maintain a symptom diary after training;
  • Willing to provide information on pregnancy and neonatal outcomes if care occurs outside GMC;
  • Willing to permit venous blood draws on at least 4 timepoints --1) Baseline study visit, 2)28-34 weeks, 3) 37 weeks - prior to delivery and 4) after delivery;
  • Willing to permit blood draws if hospitalized at GMC for COVID-19 infection;
  • Willing to consent to participate in the study

Exclusion criteria

  • Anyone who is deemed to have limited decision-making capacity as defined by Boston University IRB i.e. Substantial impairment of cognitive functions (e.g. attention, comprehension, memory, and intellect), or conditions that might affect their cognitive functions.
  • Anyone who is deemed to have limited capacity to consent as defined by Boston University Institutional Review Board (IRB) i.e. The ability to provide legally effective consent to enroll in a research study (AAHRPP definition).

Treatment and study plan

Exposures

Other

COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn

Primary outcomes

  1. Maternal composite adverse outcome variable

    Time frame: 1 year

    The maternal composite variable includes any of following 3 outcomes:

    • Preterm labour, defined as hospitalization for the management of onset of labor before fetus age 37 weeks, regardless of when birth occurs;
    • Pre-eclampsia with severe features, defined as the new onset of systolic blood pressure >160 mm Hg and/or diastolic blood pressure >110 mm Hg and proteinuria (World Health Organization (WHO) definition);
    • Mortality at any time between enrolment and day 42 post-partum/after miscarriage.

Secondary outcomes

  1. Perinatal composite adverse outcome variable

    Time frame: 1 year

    The perinatal adverse outcomes includes any of the following 3 outcomes:

    • Preterm birth, defined as gestational age of <37 weeks at birth, based on gestational age dating by ultrasound obtained before study enrolment;
    • Neonatal critical illness, defined as any sign of critical illness in the newborn and/or continued hospitalization after day 7 of life;
    • Perinatal Mortality, defined as fetal mortality after week 20 of pregnancy through neonatal death by day 7 of life

Study contacts

Contact information is provided by the study sponsor or research team.

Aboli Goghari, MPH

CONTACT

[email protected]

617-358-2310

Patricia Hibberd, MD PhD

CONTACT

[email protected]

617-358-2046

Sponsors and collaborators

Lead sponsor

Boston University

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Lata Medical Research Foundation, Nagpur

Registry information

Official study title

Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE) Study in India

Acronym: ICOPE

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Dec 13, 2023
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.